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The resonanceenhanced Raman spectrum of eosinophil peroxidase (EPO) from horse and human eosino- 
phils is reported. Based upon the spectral energies, distribution and depolarization ratios of the high-fre- 
quency skeletal modes and upon the presence ofweak bands assignable tovinyl substituent groups, we con- 
clude that the heme prosthetic group is high-spin, 6 coordinate protoporphyrin. The Raman spectrum 
reveals clear differences from lactoperoxidase (LPO), an enzyme which appears nearly structurally isomor- 
phous by other physical techniques; the data indicate astronger axial 6th ligand in EPO. Mechanistic mpli- 
cations are discussed in relation to LPO and myeloperoxidase, an enzyme present in neutrophils and mono- 
cytes which contains a unique functional active-site chlorin. 
Chlorin Eosinophil Enzme mechanism Peroxidase Protoheme Raman spectroscopy 
1. INTRODUCTION 
The neutrophil peroxidase, myeloperoxidase 
(MPO), is capable of catalyzing the two-electron 
peroxidation of the chloride ion to hypochlorous 
acid (HOCl) [l]. Several lines of evidence suggest 
that HOC1 formed in this way is an important 
microbicidal agent in stimulated polymor- 
phonuclear leukocytes [2,3]. 
The heme functional group of MPO is covalent- 
ly bound to the protein and undergoes chemical 
modification upon attempts to isolate it [4]. This 
circumstance has hindered identification of the 
heme structure by conventional means. We have 
recently demonstrated by resonance-enhanced 
Raman spectroscopy that the heme of canine MPO 
is a chlorin [5]. Others have shown that the human 
enzyme gives a nearly identical resonance Raman 
spectrum and similarly concluded that its pro- 
sthetic group is a chlorin [6]. This assignment is 
consistent with physical properties of the enzyme 
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measured by other techniques [7] but is at odds 
with chemical derivatization studies, which have 
suggested that the heme is a formylporphyrin 141. 
The functional significance of an active site 
chlorin is unclear. In general, Compound I ferry1 
a-cations of porphyrin-containing peroxidases are 
incapable of oxidizing chloride ions, presumably 
because the energetics are unfavorable. Ring 
reduction to form the corresponding chlorins 
would be expected to decrease the Compound I 
potential by about 200 mV [8]; on thermodynamic 
grounds, therefore, chlorins are expected to be less 
effective catalysts of halide oxidation than struc- 
turally analogous porphyrins. We have suggested 
two possible ways in which chlorins might 
facilitate chloride ion oxidation [5]. Axial binding 
of the weak-field chloride ion to heme iron might 
be promoted in the MPO chlorin because the 
greater flexibility of hydroporphyrin rings brought 
about by disruption of ring zr-conjugation permits 
relatively easy adjustment in core size, facilitating 
central metal binding of diverse ligands [9]. This 
explanation appears unlikely in view of recent 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/85/23.30 0 1985 Federation of European BiochemicaLSocieties 271 
Volume 189, number 2 FEBS LETTERS September 1985 
kinetic studies that identify the MPO heme 
chloride-binding site as inhibitory [lo]. Alter- 
natively, the presence of a chlorin Compound I 
may favor chloride ion oxidation by a peripheral 
ring position. The predominant reaction between 
chloride ion and metalloporphyrin a-cations [l l] 
and other aromatic s-cations [12] appears to be 
electron transfer, rather than nucleophilic addition 
leading to ring chlorination. Reduction of HOC1 is 
extraordinarily sensitive to the nucleophilic 
character of the reductant [13]. Assuming the 
reverse process, chloride ion oxidation, occurs 
through a transition state with similar properties, 
reactivity will be controlled by the electrophilic 
character of the oxidant electron acceptor site. As 
a consequence of having one of their pyrrole rings 
reduced, chlorin ferry1 r-cations possess a ring 
charge asymmetry not found in analogous por- 
phyrins [14]. This asymmetry might provide an 
unusually reactive electron-deficient peripheral site 
for chloride ion oxidation. 
To test these postulated structure-function rela- 
tionships, we use resonance Raman spectroscopy 
to identify the active-site heme group in eosinophil 
peroxidase (EPO). This enzyme is also capable of 
chloride ion peroxidation [ 151. It has been propos- 
ed to contain active site iron protoporphyrin [16] 
based upon the resemblance of its optical and elec- 
tron paramagnetic resonance spectra to those of 
lactoperoxidase (LPO), an enzyme known to con- 
tain protoporphyrin [ 171. Resonance Raman spec- 
troscopy permits assignment of spectral features to 
discrete functional groups of a chromophore, 
thereby providing a more definitive analysis of 
structure. 
2. MATERIALS AND METHODS 
Horse EPO was purified as described [ 181. The 
final preparation, which was in 0.05 M sodium 
acetate buffer, pH 4.7, containing 1.0 M NaCl, 
had an _‘&/&so nm ratio of 1.05. The human 
EPO preparation was the void volume of a 
Sephadex G-50 chromatographic separation of 
solubilized human eosinophil granules from a pa- 
tient with eosinophilia [19] (kindly provided by Dr 
Gerald Gleich). This preparation was in 0.05 M 
sodium acetate buffer, pH 4.3, containing 0.15 M 
NaCl. Based upon the molar extinction coefficient, 
~4~3 = 110 mM-‘-cm-’ [16], the effective perox- 
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idase concentration of the human preparation was 
1.8 x 10m5 M; the measured absorbance ratio 
A413/A2,5 was 0.38. Raman spectra were obtained 
for the suspensions using previously described pro- 
cedures and instrumentation [5]; no evidence of 
sample degradation was observed in successive 
scans. Cyanide derivatives were prepared by spec- 
trophotometric titration with solid potassium 
cyanide (Baker reagent grade) [5]. 
3. RESULTS 
Chlorin resonance Raman spectra typically con- 
tain a relatively large number of bands [20], many 
of which are intense [21]. Raman spectra of horse 
or human EPO (figs 1 and 2) do not show these 
features, but instead are similar to known 
protoporphyrin-containing proteins, e.g. hemo- 
globin [22], intestinal peroxidase [23], horseradish 
peroxidase [24] and lactoperoxidase [25]. Further- 
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Fig.1. Resonance Raman spectra of EPO under 
406.7 nm excitation, 90” scattering geometry, -4”C, 
scan rate 1 cm-‘. s-l. Spectrum A: oxidized horse 
enzyme, 14 mW incident power, 6 scans. Spectrum B: 
oxidized human enzyme, 30 mW, 2 scans. Spectrum C: 
cyanide-derivative of human enzyme, 32 mW, 9 scans. 
Inset: oxidized human enzyme, low-frequency region, 
conditions as in B. Asterisk indicates laser plasma 
emission line. Oxidized human enzyme band frequencies 
and depolarization ratios (II/Ill): 1613 (0.3); 1581 (0.3); 
1557 (0.2); 1512 (0.2); 1477 (0.3); 1418 (0.7); 1365 (0.3); 
1207 (0.3); 1167 (0.5); 1116 (0.3); 988 (0.5). 
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more, several anomalously polarized vibrational 
bands (II/Z,, > 3/4) are observed with excitation 
into the heme visible absorption bands. With 
514.5 nm laser excitation, these bands are found at 
1560, 1423, 1389, 1337 and 1302 cm-’ (fig.2). The 
appearance of anomalously polarized bands re- 
quires that the heme be a relatively high-symmetry 
porphyrin [26,27]. This excludes low-symmetry 
chlorin, which exhibits only polarized modes 
(Z,/I,, < 3/4) [5,21]. 
Additional information regarding the porphyrin 
structure can be obtained from the Raman spec- 
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Fig.2. Resonance Raman spectra of human EPO under 
514.5 nm excitation. Spectrum A: oxidized enzyme, 
parallel polarized light, -4*C, 75 mW incident power, 
17 scans, scan rate 1 cm-’ *s-l, 90” scattering geometry. 
Spectrum B: same as A except perpendicular polarized 
light. Asterisk indicates an emission line (435.8 nm) of 
the external f uorescent room lighting. Band frequencies 
and depolarization ratios (II /Zr): 1623 (0.6); 1422 (1.3); 
1389 (1.0); 1370 (0.4); 1340 (1.0); 1300 (1.2); 1210 (0.4); 
1170 (0.6); 1003 (0.3). 
trum [28]. The positions of the oxidation state 
marker band (~4) at 1365 cm-’ in the resting en- 
zyme (fig.lA,B) and at 1366 cm-’ in the cyan0 
derivative (fig.lC) indicate that the central iron is 
ferric; the heme appears to be 6-coordinate, based 
upon a ~10 band frequency of 1614 cm-’ 
(fig.lA,B) 1291. The shift in the core-size marker 
band (YI I) from 1557 to 1572 cm-’ accompanying 
cyanide addition indicates ligation occurs with 
high-to-low spin conversion of the ferric electronic 
configuration. The presence of vinyl substituent 
groups on the porphyrin ring can be inferred from 
weak bands at 1620 [YC=&)], 1336 
[&(=CH2)(2)], 1304 [&CH=)] and 1167 cm-’ 
[vQ,-c,(l)] under Soret excitation (fig.lB), and at 
1423 [&,j=Cf-I~)(l)] and 1337 cm-’ [&(=CH2)(2)] 
under visible excitation (fig.ZB). Band assignments 
given in brackets correspond to those determined 
for meta~oprotoheme complexes from frequency 
shifts accompanying deuteration [30,31]. 
4. DISCUSSION 
The Raman spectra presented here suggest hat 
the prosthetic group of EPO, like most other 
peroxidases, is protoheme. This conclusion is con- 
sistent with other studies in which the optical and 
EPR properties of EPO derivatives were shown to 
be very similar to LPO, a protoheme-containing 
enzyme 116,171. Hyperfine splitting of the EPR 
signal from the ferrous nitrosyl derivatives has 
established that one of the axial ligand atoms is 
nitrogen for both enzymes, as well as for MPO 
1321. In LPO, the axial group has been shown to be 
a histidine imidazole ring [33]; because the ligand 
field parameters of other low-spin derivatives of 
LPO and EPO are very similar, it is likely that 
histidine is also axially bound to the EPO heme. 
Thus, at least 5 of the 6 ligation sites may be struc- 
turally isomorphous in the 2 enzymes. 
The resonance Raman spectra of LPO and EPO, 
although qualitatively quite similar, compare less 
favorably than EPR and optical properties. 
Specifically, the skeletal deformation modes in the 
high frequency region (~10, 1613 cm-‘; ~2, 
1581 cm-‘; ~11, 1557 cm-‘; ~3, 1512 cm -1. 9 P281 
1477 cm-‘) for human EPO are all shifted 
5-10 cm-r to lower energies relative to LPO, with 
the horse enzyme exhibiting intermediate shifts. 
The positions of these bands have been shown to 
273 
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correlate inversely with the porphyrin core size in 
protoporphyrins [30]. Accordingly, the porphyrin 
ring size is larger in EPO, which implies that the 
heme iron assumes a more in-plane position in this 
enzyme. In-plane alignment would be favored if 
the 6th ligand were more strongly g-donating in 
EPO than LPO. Also, the position of the v4 band, 
at 1365 cm-’ in EPO and 1373 cm-’ in LPO, is 
considered to monitor the extent of a- 
delocalization in the porphyrin ring [25,34]. By 
this criterion, the ring density is greater in native 
EPO than LPO, again consistent with the presence 
of a stronger field 6th ligand. Alternatively, this 
shift could arise from differing protein-heme in- 
teractions, e.g. r-overlap with aromatic residues, 
in the 2 enzymes. Unlike EPO, LPO is unable to 
catalyze chloride ion peroxidation despite the 
overall similarity of the heme environments. It 
may be that subtle structural variations of the type 
revealed in the Raman spectra can ultimately ac- 
count for the reactivity differences, e.g., in terms 
of differing Compound I reduction potentials, but 
the molecular bases for such effects are not 
presently understood. 
The MPO chlorin is also 6-coordinate, high 
spin, with axial ligands including nitrogen and a se- 
cond, relatively weak-field group [5-7,23,32,33]. 
Since both EPO and MPO are able to use chloride 
ion in catalyzing halogenation reactions, the MPO 
chlorin is not obligatory for such activity. It has 
been noted, however, that the cellular toxicity of 
EPO-HzO&I- reaction systems is substantially 
less than MPO-H202-Cl- [35]. In these reactions, 
the selectivity of EPO for iodide and bromide over 
chloride appears much greater than in the MPO 
assay systems. The capabilities of EPO towards 
chloride ion peroxidation are therefore substantial- 
ly less than MPO, indicating markedly diminished 
catalytic efficiency for the porphyrin-containing 
enzyme. It has also been reported that EPO is 
unable to catalyze certain chlorination reactions 
that are facile for MPO, e.g. amino acid decarbox- 
ylations that proceed via chloramine intermediates 
[36]. Myeloperoxidase can catalyze formation of 
free HOC1 [l], which is then thought to react 
chemically as opposed to enzymatically, with 
substrate. If EPO also serves just to catalyze the 
formation of HOCl, no fundamental reactivity dif- 
ferences would be expected for the two systems. 
The catalytic mechanisms may therefore differ; 
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one possibility is that EPO halogenation entails in- 
teraction of substrate with an enzyme-hypohalite 
complex. The observations that LPO [37] and 
chloroperoxidase [38], enzymes which appear to 
react by this mechanism, can form freely diffusible 
hypohalous acids in the absence of substrate, do 
little to support this contention, however. The 
question of halide specificity in peroxidase- 
catalyzed halogenation mechanisms remains an in- 
triguing puzzle. 
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